Advanced Search
MyIDEAS: Login

Citations for "Pharmaceuticals and the Developing World"

by Michael Kremer

For a complete description of this item, click here. For a RSS feed for citations of this item, click here.
as in new window
  1. Jeffrey Clemens, 2012. "The Effect of U.S. Health Insurance Expansions on Medical Innovation," Discussion Papers 11-016, Stanford Institute for Economic Policy Research.
  2. Chris Papageorgiou & Andreas Savvides & Marios Zachariadis, 2005. "International Medical Technology Diffusion," University of Cyprus Working Papers in Economics 2-2005, University of Cyprus Department of Economics.
  3. Harsha Thirumurthy & Joshua Graff Zivin & Markus Goldstein, 2006. "The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya," Working Papers 947, Economic Growth Center, Yale University.
  4. Reto Foellmi & Josef Zweimüller, 2003. "Inequality and Economic Growth: European Versus U.S. Experiences," CESifo Working Paper Series 1007, CESifo Group Munich.
  5. Hendrik P. van Dalen & Mieke Reuser, 2005. "What drives Donor Funding in Population Assistance Programs?," Tinbergen Institute Discussion Papers 05-062/1, Tinbergen Institute.
  6. David Cutler & Angus Deaton & Adriana Lleras-Muney, 2005. "The Determinants of Mortality," Working Papers 164, Princeton University, Woodrow Wilson School of Public and International Affairs, Research Program in Development Studies..
  7. Petra Moser, 2012. "Patent Laws and Innovation: Evidence from Economic History," NBER Working Papers 18631, National Bureau of Economic Research, Inc.
  8. Kyle, Margaret K & McGahan, Anita M, 2011. "Investments in Pharmaceuticals Before and After TRIPS," CEPR Discussion Papers 8371, C.E.P.R. Discussion Papers.
  9. Petra Moser & Alessandra Voena, 2010. "Compulsory Licensing: Evidence from the Trading with the Enemy Act," Discussion Papers 09-026, Stanford Institute for Economic Policy Research.
  10. Gino Gancia, 2003. "Globalization, Divergence and Stagnation," Working Papers 198, Barcelona Graduate School of Economics.
  11. Padmashree Gehl Sampath, 2010. "Economic Aspects of Access to Medicines after 2005: Product Patent Protection and Emerging Firm Strategies in the Indian Pharmaceutical Industry," Working Papers id:3336, eSocialSciences.
  12. Kessing, Sebastian & Nuscheler, Robert, 2003. "Monopoly pricing with negative network effects: the case of vaccines," Discussion Papers, Research Unit: Market Processes and Governance SP II 2003-06, Social Science Research Center Berlin (WZB).
  13. Y. Wang, 2006. "Price competition in the chinese pharmaceutical market," International Journal of Health Care Finance and Economics, Springer, vol. 6(2), pages 119-129, June.
  14. Tomas Philipson & Stephane Mechoulan & Anupam Jena, 2006. "Health Care, Technological Change, and Altruistic Consumption Externalities," NBER Working Papers 11930, National Bureau of Economic Research, Inc.
  15. David M. Cutler & Ellen Meara & Seth Richards, 2009. "Induced Innovation and Social Inequality: Evidence from Infant Medical Care," NBER Working Papers 15316, National Bureau of Economic Research, Inc.
  16. Md. Nurul Amin & Tetsushi Sonobe, 2013. "The success of the industrial development policy in the pharmaceutical industry in Bangladesh," GRIPS Discussion Papers 13-07, National Graduate Institute for Policy Studies.
  17. Chris Papageorgiou & Petia Stoytcheva, . "What Do We Know About the Impact of AIDS on Cross-Country Income So Far?," Departmental Working Papers 2005-01, Department of Economics, Louisiana State University.
  18. Bastian Rake, 2013. "Determinants of Pharmaceutical Innovation: The Role of Technological Opportunities Revisited," DRUID Working Papers 13-03, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
  19. Saradindu Bhaduri & Thomas Brenner, 2013. "Examining the determinants of drug launch delay in pre-TRIPS India," The European Journal of Health Economics, Springer, vol. 14(5), pages 761-773, October.
  20. Hendrik P. van Dalen & Mieke Reuser, 2005. "What drives Donor Funding in Population Assistance Programs?," Tinbergen Institute Discussion Papers 05-062/1, Tinbergen Institute.
  21. Murray, Fiona & Stern, Scott & Campbell, Georgina & MacCormack, Alan, 2012. "Grand Innovation Prizes: A theoretical, normative, and empirical evaluation," Research Policy, Elsevier, vol. 41(10), pages 1779-1792.
  22. Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
  23. Margaret E. Blume-Kohout & Neeraj Sood, 2008. "The Impact of Medicare Part D on Pharmaceutical R&D," NBER Working Papers 13857, National Bureau of Economic Research, Inc.
  24. Paul Grootendorst, 2009. "How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 246, McMaster University.
  25. Patricia M. Danzon & Eric L. Keuffel, 2013. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484 National Bureau of Economic Research, Inc.
  26. Ghauri, Pervez N. & Rao, P.M., 2009. "Intellectual property, pharmaceutical MNEs and the developing world," Journal of World Business, Elsevier, vol. 44(2), pages 206-215, April.
  27. Ken Tabata & Testuya Shinkai & Satoru Tanaka & Makoto Okamura, 2005. "Parallel Imports, Drag Price Control and Pharmaceutical Innovation," Discussion Paper Series 26, School of Economics, Kwansei Gakuin University, revised Aug 2005.
  28. Arvate, Paulo & Barbosa, Klenio de Souza & Gambardella, Dante, 2013. "Generic-branded drug competition and the price for pharmaceuticals in procurement auctions," Textos para discussão 333, Escola de Economia de São Paulo, Getulio Vargas Foundation (Brazil).
  29. Chris Papageorgiou & Andreas Savvides & Marios Zachariadis, . "International Medical R&D Spillovers," Departmental Working Papers 2004-03, Department of Economics, Louisiana State University.
  30. Shandre M. Thangavelu & Sanja Samirana Pattnayak, 2006. "Linkages and Spillovers from Foreign Ownership in the Indian Pharmaceutical Firms," Development Economics Working Papers 22579, East Asian Bureau of Economic Research.
  31. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2009. "Nuove politiche per l'innovazione nel settore delle scienze della vita," Working Papers 03-2009, Competitività Regole Mecati (CERM).
  32. Clive Bell & Carsten Fink, 2005. "Aide et santé," Revue d’économie du développement, De Boeck Université, vol. 19(2), pages 135-166.
  33. Shandre M. Thangavelu & Sanja Samirana Pattnayak, 2006. "Linkages and Spillovers from Foreign Ownership in the Indian Pharmaceutical Firms," SCAPE Policy Research Working Paper Series 0605, National University of Singapore, Department of Economics, SCAPE.
  34. David Popp, 2012. "The Role of Technological Change in Green Growth," NBER Working Papers 18506, National Bureau of Economic Research, Inc.
  35. Entorf, Horst & Fegert, Jörg & Kölch, Michael, 2004. "Children in need of medical innovation," Darmstadt Discussion Papers in Economics 22605, Darmstadt Technical University, Department of Business Administration, Economics and Law, Institute of Economics (VWL).
  36. Tomas Philipson & Stephane Mechoulan, 2003. "Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets," NBER Working Papers 9598, National Bureau of Economic Research, Inc.